In consultation: Guidance and quality standards
Showing 11 to 15 of 15
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Pharmalgen for the treatment of bee and wasp venom allergy | Review proposal consultation | Technology appraisal guidance | |
| Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma | Review proposal consultation | Technology appraisal guidance | |
| Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] | Final draft guidance | Technology appraisal guidance | |
| Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |